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Abstract
Shiga toxin 2 (Stx2)-producing Escherichia coli (STEC) causes hemorrhagic colitis and hemolytic uremic syndrome
(HUS) that can lead to fatal encephalopathies. Neurological abnormalities may occur before or after the onset of
systemic pathological symptoms and motor disorders are frequently observed in affected patients and in studies with
animal models. As Stx2 succeeds in crossing the blood-brain barrier (BBB) and invading the brain parenchyma, it is
highly probable that the observed neurological alterations are based on the possibility that the toxin may trigger the
impairment of the neurovascular unit and/or cell damage in the parenchyma. Also, lipopolysaccharide (LPS)
produced and secreted by enterohemorrhagic Escherichia coli (EHEC) may aggravate the deleterious effects of Stx2
in the brain. Therefore, this study aimed to determine (i) whether Stx2 affects the neurovascular unit and
parenchymal cells, (ii) whether the contribution of LPS aggravates these effects, and (iii) whether an inflammatory
event underlies the pathophysiological mechanisms that lead to the observed injury. The administration of a sub-
lethal dose of Stx2 was employed to study in detail the motor cortex obtained from a translational murine model of
encephalopathy. In the present paper we report that Stx2 damaged microvasculature, caused astrocyte reaction and
neuronal degeneration, and that this was aggravated by LPS. Dexamethasone, an anti-inflammatory, reversed the
pathologic effects and proved to be an important drug in the treatment of acute encephalopathies.
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Introduction
Shiga toxin (Stx)-producing Escherichia coli (STEC) causes
hemorrhagic colitis and Hemolytic Uremic Syndrome (HUS) [1],
the triad of thrombocytopenia, microangiopathic hemolytic
anemia and acute renal failure [2], and it is the main cause of
acute renal failure and the second cause of chronic renal
failure and renal transplantation in children in Argentina [3].
Furthermore, central nervous system (CNS) alterations caused
by STEC are a leading cause of mortality among children
during the period of acute illness [4–6].
In North America and Europe, 0.72 to 1.44 cases of HUS per
100,000 population are reported each year [7]. The largest
outbreak of HUS in Europe took place between the months of
May and July 2011 and began in northern Germany. HUS was
diagnosed in 855 patients out of a total of 3,842 patients
infected with STEC O104: H4. The death toll in Germany was
53 [8,9]. Currently Argentina has the highest occurrence of
HUS worldwide, with approximately 420 cases reported
annually and an incidence of 17/100,000 in children under 5
years of age [10]. It has been reported that the mortality rate
derived from HUS ranges between 0–5% of the cases, and
7-40% when the CNS is involved [11–13].
Approximately 35% of the patients with HUS progress to
CNS dysfunction [14–22] but 9-15% of patients have CNS
dysfunction even before the first symptoms of HUS, suggesting
that damage in the CNS may occur before or concomitantly
with other symptoms of the systemic disease [15,16]. CNS
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symptoms in STEC disease range from decerebrate posture,
hemiparesis, ataxia and cranial nerve palsy to ophthalmological
dysfunctions, hallucinations, seizures and changes in level of
consciousness (from lethargy to coma) [23–26]. Symptoms in
mice include lethargy, shivering, abnormal gait, hind limb
paralysis, spasm-like seizure, reduced spontaneous motor
activity, abnormal gait and pelvic elevation [27,28]. Previous
reports claim that severe and even fatal encephalopathy is due
to damage found in the microvasculature, neurons and/or
astrocytes that compromise normal functioning of the
neurovascular unit [23,27,28].
In addition to the known deleterious effects of Stx2, the
gram-negative EHEC releases the endotoxin
lipopolysaccharide (LPS). LPS is a component of the outer
membrane that has no direct cytotoxic action but rather
induces a variety of inflammatory mediators when secreted in
the gut [29].
In the present study, the harmful cytotoxic effects of co-
administration of LPS and Stx2 were studied in the
neurovascular unit by the use of specific cell markers.
Lycopersicon esculentum lectins, NeuN, glial fibrillary acidic
protein (GFAP) and vascular endothelial growth factor (VEGF)
antibodies were employed to study distribution of endothelium
glycocalyx [30], early signs of neuronal degeneration [31],
reactive astrocytes [32], and angioplasticity (angiogenic
adaptational changes) [33].
Given that neurological alterations are commonly observed
in the motor cortex as well as motor disturbances in STEC-
infected patients [23–26], the cell alterations produced in this
brain region were specifically analyzed. The study of this area
could be clinically relevant to determine predictive factors for
generalized seizures and/or other disorders produced in this
brain area that may lead to death [8,11–14,17,25,27].
Animal models have been established and analyzed to
define the nature of a disease in humans. To this end, animal
models must resemble the human disease [34]. Therefore, the
objective of this paper was (i) to study the contribution of LPS
to pathogenicity in the neurovascular unit in mice brain
following systemic administration of a sub-lethal dose of Stx2,
and (ii) to determine whether these pathogenic changes
include an inflammatory component. To this end, the
glucocorticoid Dexamethasone, an anti-inflammatory and
possible neuroprotectant, was challenged to neutralize the
toxic action of LPS with Stx2.
Materials and Methods
Stx2 Protein Purification
Stx2 was purified by affinity chromatography under native
conditions as previously described [35].
Briefly, recombinant E. coli DH5a containing pStx2 were
cultured overnight. The supernatant obtained was precipitated
in 60% SO4 (NH4) 2 1 mM PMSF, and the pellet was dialyzed
overnight, resuspended in phosphate buffer solution (PBS) with
a cocktail of protease inhibitors, and incubated with Globotriose
Fractogel Resin (IsoSep AB, Tullinge, Sweden). The resin was
washed and the toxin eluted with MgCl2. Protein concentration
was determined in all the eluates. Protein content in all the
fractions was monitored by silver/Coomassie blue staining [36],
and the presence of Stx2 in the eluates was confirmed by
Western Blot analysis. Results showed a 7.7-kDa band
corresponding to Stx2B and a 32-kDa band corresponding to
Stx2A. The same batch of toxin was used for all the
experiments. The cytotoxic capacity of Stx2 was assessed in
Vero cells by the neutral red assay and the cytotoxic dose 50
(CD50) found was about 1 pg/ml [37]. This effect was
neutralized by means of preincubation with an anti-subunit 2B
monoclonal antibody (Sifin, Berlin, Germany), and not
neutralized when using an isotype antibody instead [37].
Lipopolysaccharide (LPS) was removed from the Stx2 solution
by using Detoxi-gel (Pierce, Rockford, USA). This Stx2 solution
contained less than 0.03 endotoxin units/ml.
Neurovascular Toxicity Assays
Ninety-six female pathogen-free NIH mice weighing 25-30g
were housed in an air conditioned and light-controlled (lights on
between 06:00 am and 06:00 pm) animal facility. They were
then separated into groups and subjected to the following
intravenous (i.v.) treatments: LPS (428.6ng); Stx2 (0.5ng); LPS
+Stx2 (0.5ng Stx2+ 428.6ng LPS); vehicle infusion (saline
solution) (Table 1). Each animal received two i.v. doses in the
lateral tail vein (half the total amount and 100 µl per injection
for each treatment) at an interval of 24 hours. Food and water
were provided ad libitum. Six mice per group were
anesthetized with chloral hydrate (350 mg/kg) and perfused
transcardially with 0.9% NaCl solution followed by 4%
paraformaldehyde in 0.1 M phosphate buffer solution (PBS)
[fixative per animal weight (ml/g)] at the following time intervals
after the respective treatment: 2, 4, 7 and 20 days. The LPS
used was from E. coli O157:H7 (Sigma, Saint Louis, MO,
USA). Brains were removed from the skull and post-fixed with
the same fixative solution for 2 hours, and cryoprotected
through a daily sequenced passage of increasingly
concentrated sucrose solutions (10, 20 and 30%). Brain
coronal sections (25 µm thick) were cut with a cryostat,
maintained in a cryoprotectant solution (50% PBS 0.1 M, 30%
Ethylene glycol, 20% Glycerol) at -20 °C, and subsequently
processed for immunofluorescence microscopy.
The experimental protocols and euthanasia procedures were
reviewed and approved by the Institutional Animal Care and
Use Committee of the School of Medicine of Universidad de
Buenos Aires, Argentina (Resolution No. 2437/2012). All the
procedures were performed in accordance with the EEC
guidelines for care and use of experimental animals (EEC
Council 86/609).
Lectin Histofluorescence
Six floating sections (the same number of sections was used
for all immunofluorescence assays performed) for each
treatment were subjected to Lycopersicum esculentum lectin
histochemical marker to study the motor cortex endothelial
cells. After several rinses with 10 mM PBS, sections were
incubated with biotinylated lectin-10µg/ml 0.3% Triton X-100 in
the same buffer (4°C for 24 hours), and subsequently
incubated with Alexa-488 Streptavidin (1:100) 0.3% Triton
X-100 for 1 hour at room temperature (RT), rinsed 3 times with
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10 mM PBS and mounted on slides with a solution of glycerol
and PBS 3:1 (sections for other immunofluorescence assays
were also mounted in the same solution). Controls were
performed using the same procedure but without adding the
lectin protein. A green fluorescence filter was used to visualize
brain cortex microvessels, and Adobe Photoshop software to
assemble the images and obtain merged images (the same
procedure was used for the other immunofluorescence
assays).
VEGF Immunofluorescence
After several rinses with 10 mM PBS, brain floating sections
were incubated to determine the expression of the vascular
endothelial growth factor (VEGF), first with the same buffer but
with 0.1% Triton X-100 for one hour, followed by normal goat
serum 10% with 0.3% Triton X-100 in PBS, also for one hour.
The sections were subsequently incubated with anti-VEGF
antibody diluted at 1:500 in 10mM PBS with 0.3% Triton X-100
at 4 °C for 48 hours. After several rinses with Triton X-100
0.025% sections were incubated with goat IgG anti-mouse/
Texas Red diluted at 1:200 in the same buffer with 0.3% Triton
X-100 for 2 hours at RT. Finally, sections were rinsed with
10mM PBS and mounted on slides. Controls were performed
using the same procedure but without adding the primary
antibody for VEGF. A red fluorescence filter was used for
visualization of immunofluorescence to VEGF localization.
NeuN Immunofluorescence
After several rinses with 10 mM PBS, sections were
incubated with 10 mM PBS Triton X-100 0.1% for one hour,
followed by normal goat serum 10% with 0.3% Triton X-100 in
the same solution, also for one hour. Sections were
subsequently incubated with anti-NeuN antibody diluted at
1:500 in 10mM PBS with 0.3% Triton X-100 at4°C for 48 hours.
Table 1. Diagram of the study.
Experiment n Treatment
Days of
treatment
Total
number of
mice
Neurovascular
Toxicity Assays 6 Vehicle 2, 4, 7, 20 96
  LPS   
  Stx2   
  Stx2+LPS   
Neurovascular
Protection Assays 4 Vehicle 4 32
  LPS + Saline solution   
  Stx2 + Saline solution   
  Stx2+LPS + Salinesolution   
  Dexamethasone   
  LPS + Dexamethasone   
  Stx2 + Dexamethasone   
  Stx2+LPS +Dexamethasone   
After several rinses with 10mM PBS Triton X-100 0.025%
sections were incubated with goat IgG anti-mouse/Texas Red
diluted at 1:200 with 0.3% Triton X-100 in the same buffer for 2
hours at RT. Finally, sections were rinsed with 10mM PBS and
mounted on slides. Controls were performed using the same
procedure but without adding the primary antibody. A red
fluorescence filter was used for visualization of the NeuN
immunofluorescence.
GFAP Immunofluorescence
After several rinses with 10 mM PBS, brain floating sections
were incubated with 10 mM PBS 0.1% Triton X-100 for one
hour, followed by normal goat serum 10% in PBS 0.3% Triton
X-100 for another hour. Sections were then incubated with anti-
GFAP antibody (dilution 1:500) in 10 mM PBS 0.3% Triton
X-100 at 4°C for 48 hours. After several rinses with 10 mM
PBS Triton X-100 0.025%, brain sections were incubated with
goat IgG anti-Rabbit/Texas Red (dilution 1:200) in 10mMPBS
Triton X-100 0.3% for one and a half hours at RT. Finally,
sections were rinsed in 10 mM PBS and mounted on slides.
Controls were performed using the same procedure but without
adding the primary antibody. A red fluorescence filter was used
for visualization of GFAP immunofluorescence.
Merging Images
The procedure described above was employed to obtain
merged images of GFAP and lectin immunofluorescence
and/or VEGF and lectin immunofluorescence. The lectin
histofluorescence protocol was always performed after GFAP
or VEGF immunofluorescence. All analyses were carried out in
the same comparable areas.
Neurovascular Protection Assays
Thirty-two female mice divided into eight groups of 4 mice
each were used for this experiment (two groups treated with
vehicle, two with LPS, two with Stx2 and two with Stx2+LPS as
described above, table 1). Four of these groups were treated
with 7.5 mg/kg i.p. Dexamethasone (100 µl per dose) twice a
day for 3 days, starting when they received their respective i.v.
treatment (vehicle, LPS, Stx2 or Stx2+LPS), and perfused on
the fourth day as described above; the other half received 100
µl of i.v. saline solution twice a day, also for three days, and
were perfused on the fourth day. The perfusion and treatment
procedures to obtain the brains were performed as previously
described.
Analysis of Micrographs
A total of 32 brain motor cortex micrographs per treatment
were analyzed. For this purpose, eight different sections per
treatment were obtained and two micrographs were taken from
each hemisphere. Micrographs were taken between cortical
layers II (external granular layer) and V (internal pyramidal
layer) of M1 and M2 [38] to determine neurodegeneration
(NeuN), endothelial damage (lectins), expression of vascular
endothelial growth factor (VEGF), and reactive astrocytes
(GFAP). A fluorescence Axiophot Zeiss microscope with a 20x
objective lens was used. The images obtained were analyzed
Dexamethasone Reduces Stx2 Neurotoxicity
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using the ImageJ software (NIH). Two criteria were used to
analyze endothelial damage: changes in glycocalyx expression
in microvessels (as the number of glycocalyx particles bound to
lectins) and density of microvessels (as the percentage of area
occupied by microvessels). The particles analyzed were
quantified by conversion into 8-bit and contrast against the
background. Moreover, objects with an area less than 10 µm2
were excluded to avoid quantified dots from the background. In
addition, VEGF immunopositive particles were quantified as
described above. Acquired images were opened using Adobe
Photoshop CS software to determine neurodegeneration, and
nuclei with normal phenotype were quantified and painted to
avoid errors. These data were represented as the percentage
of degenerated nuclei in respect of total nuclei per micrograph.
The ROI Manager tool on Image-J software was employed to
quantify the expression of GFAP and to determine reactive
astrocytes. The mean gray option was selected and integral
optical density (IOD) was employed to obtain the mean of a
grayscale.
Statistical Analysis
The data are presented as mean ±SEM. In the case of
different toxicity treated-groups and their respective controls
were challenged with dexamethasone at one time point (4 days
of treatment) in the neurovascular protection assays, statistical
significance was performed using one-way analysis of variance
(ANOVA) followed by Student-Newman-Keuls post hoc tests.
In the case of comparison of different treatment groups at
different time points in the neurovascular toxicity assays, two-
way analysis of ANOVA was used followed Bonferroni post hoc
test (GraphPad Prism 4, GraphPad Software, Inc.). The
criterion for significance was p<0.001 for all the experiments.
Samples subjected to the neurovascular protection assays
were independent from those assayed for neurovascular
toxicity. The number of animals and the corresponding brain
section samples used in the neurovascular protection assays
(dexamethasone assays) yielded error bars with low dispersion
and therefore it was not necessary to subject additional
animals and/or brain sections to these treatments.
Results
Intravenous administration of a sublethal dose of Stx2
changes the profile of microvessels and LPS
exacerbates these changes in the brain motor cortex
Lectin fluorescence binding to glycoconjugates was used to
detect the changes in the microvasculature profile until day
twenty of treatment. Lectins are non-immune proteins that bind
with high affinity to glycoconjugates present in the glycocalyx of
endothelial cells. Representative micrographs obtained from
saline-treated control mice showed continuous lectin
fluorescence binding throughout all microvessels. Microvessels
of saline-treated mice were well preserved, with continuous
and defined edges in comparison with those treated with the
toxins. In addition, microvessels occupied a larger area in the
cortex per observed field than microvessels treated with the
toxins (Figure 1A, E, I, M). In toxin-treated mice, discontinuous
lectin fluorescence binding distributed in patches with poorly
defined edges was observed and, consequently, the lectin
microvessel density was significantly decreased (Figure 1H).
Microvessels from Stx2 plus LPS (Stx2+LPS)-treated mice
were maximally damaged after four days of treatment (Figure
1H) compared with Stx2-alone- or LPS-alone-treated mice.
However, after twenty days, microvessels from the Stx2+LPS,
Stx2 and LPS treatments recovered a normal appearance
similar to vehicle-treated microvessels (Figure 1P). All the
observed changes in the microvasculature were confirmed by
morphometric analysis: the density of microvessels (calculated
as the percentage of microvessels that occupy a determined
area) and the number of positive glycocalyx-particles bound to
fluorescence lectins were determined. A maximal and
significant decrease in density of microvessels (p<0.001) was
observed in the Stx2+LPS-treated mice compared with the
Stx2-treated ones, and in both groups in comparison with the
saline-treated control mice between days four and seven of
treatment (Figure 1Q), while a maximal and significant increase
in the number of positive glycocalyx particles bound to
fluorescence lectins (p<0.001) was observed as a result of
microvessel fragmentation in Stx2+LPS-treated mice compared
with Stx2-treated ones, and in both groups in comparison with
saline-treated control mice between days four and seven of
treatment (Figure 1R).
Dexamethasone recovered the density of microvessels
and glycocalyx integrity
Treatment with Dexamethasone recovered glycocalyx
distribution in microvessels and significantly reduced the
number of fragmented glycocalyx particles bound to fluorescent
lectins after four days of treatment with LPS, Stx2 and
Stx2+LPS (Figure 2J). It also maintained the integrity of
microvessel edges in the three experimental groups described
(Figure 2B–D, F–H) and the density of microvessels was
increased (Figure 2I).
Intravenous administration of a sublethal dose of Stx2
inhibits the expression of VEGF, and this is
exacerbated by LPS
Following the observation that the toxins changed the profile
of microvessels, it was postulated that they could also change
the expression of VEGF, an angiogenic growth factor that may
appear under regenerative processes. An anti-VEGF antibody
was employed to evaluate whether LPS, Stx2 or both toxins
combined changed the expression of VEGF in motor cortex
microvessels. VEGF expression was observed in microvessels,
and it co-localized with glycocalyx particles bound to lectin
fluorescence (Figure 3Q). A significant decrease in the
expression of VEGF was observed two days after
administration of LPS, Stx2 and Stx2+LPS (Figure 3A–D),
although no significant differences were observed between the
Stx2 and Stx2+LPS treatments. Maximum VEGF reduction was
observed after seven days of treatment with Stx2+LPS (Figure
3H, L). Total reduction of VEGF was also observed after the
treatment with Stx2 and/or LPS as from day seven (Figure 3J,
K). However, a restoration tendency in VEGF expression was
observed after twenty days (Figure 3N–P).
Dexamethasone Reduces Stx2 Neurotoxicity
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Dexamethasone restores the basal expression of VEGF
Dexamethasone succeeded in significantly elevating the
basal expression of VEGF, which was reduced by the action of
LPS and Stx2 (Figure 4), and reestablished the inhibited
expression of VEGF caused by the treatment with Stx2+LPS
after four days of i.v. administration (Figure 4I).
Figure 1.  Changes in the expression of glycocalyx particles bound to fluorescent lectins in the cerebral microvasculature
of mice motor cortex.  Micrographs A, E, I and M show the microvasculature profile in the control groups; B, F, J and N: LPS
treatment; C, G, K and O: Stx2 treatment; D, H, L and P: Stx2+LPS treatment; at two, four, seven and twenty days after the
respective treatment. Arrows (H) show microvessels devoid of glycocalyx particles bound to fluorescent lectins. Stx2+LPS
decreased microvessel density (Q) and increased the number of positive glycocalyx particles (R). *: significant differences between
treated and control groups; **: significant differences between Stx2 and Stx2+LPS treatments (p <0.001).
doi: 10.1371/journal.pone.0070020.g001
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Intravenous administration of a sublethal dose of Stx2
produces neurodegeneration, and LPS exacerbates this
Anti-NeuN antibody was employed to determine whether
systemic administration of LPS, Stx2 or Stx2+LPS caused
neurodegeneration. A nuclear dot staining pattern by indirect
immunofluorescence and/or negative nuclear
immunofluorescence with perinuclear immunofluorescence
pattern for Neu-N confirmed a neurodegenerative phenotype,
while a conserved and homogeneous nuclear
immunofluorescence pattern for Neu-N confirmed healthy
neurons (Figure 5A). Neurons in degenerative state were
observed two days after administration of LPS, Stx2 or
Stx2+LPS (Figure 5Q). It must be noted that a significant
increase in the number of degenerated neurons was observed
in animals treated with Stx2+LPS as compared to the Stx2 or
LPS treatments after four, seven and even twenty days.
Accordingly, maximal neurodegeneration was observed four
days after administration of Stx2+LPS (Figure 5H) and it
decreased at seven and twenty days (Figure 5P).
Dexamethasone protects neurons against Stx2 and
LPS
A significant decrease in the number of degenerated neurons
in all groups treated with toxin (LPS, Stx2 or Stx2+LPS) was
observed when challenged with a dose of Dexamethasone
(Figure 6I). It was found that Dexamethasone protected about
30% of neurons against the administration of Stx2+LPS after 4
days.
Intravenous administration of a sublethal dose of Stx2
produces reactive astrocytes, and the combination with
LPS exacerbates them
The study of glial fibrillary acidic protein (GFAP) expression
by immunofluorescence was carried out to determine whether
i.v. administration of LPS, Stx2 and/or Stx2+LPS produced
reactive astrocytes. GFAP is a cytoskeletal protein produced in
astrocytes and expression thereof increases following a
noxious event. It was observed that Stx2 administration
increased the expression of GFAP in reactive astrocytes as
from two days after the LPS, Stx2 and Stx2+LPS treatment
(Figure 7R). Quantification of GFAP levels was performed by
integral optical density (IOD) imaging. Maximum expression of
GFAP was observed after four days of Stx2+LPS treatment in
Figure 2.  Dexamethasone maintains microvessel integrity.  Fluorescence micrographs show changes in the profile of
microvessels from the motor cortex after four days of treatment with saline (A and E), LPS (B and F), Stx2 (C and G) and Stx2+LPS
(D and H) followed by i.p. injection of saline (A through D) or Dexamethasone (E through H). Dexamethasone rescues microvessel
density (I) and glycocalyx distribution (J), similar to density and distribution in the control groups. K: negative control in mice motor
cortex obtained by not adding Lycopersicum esculentum lectins. *: significant differences between Dexamethasone and saline
treatments.
doi: 10.1371/journal.pone.0070020.g002
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Figure 3.  Changes in the expression of VEGF.  Micrographs A, E, I and M: basal expression of VEGF with saline treatment; B, F,
J and N: LPS treatment; C, G, K and O: Stx2 treatment; D, H, L and P: Stx2+LPS treatment; at two, four, seven and twenty days
after the respective treatment. Stx2+LPS fully decreased VEGF expression after four days of treatment until day seven (H and L).
LPS (J) or Stx2 (K) treatment fully decreased VEGF expression as from day seven. Micrograph Q shows co-localization of VEGF
and glycocalyx particles bound to lectins in the endothelium. Stx2+LPS significantly decreased VEGF expression as compared to
LPS or Stx2 treatment (R) (p <0.001). *: significant differences between the treated and saline groups. **:significant differences
between Stx2+LPS and Stx2 treatments (p <0.001).
doi: 10.1371/journal.pone.0070020.g003
Dexamethasone Reduces Stx2 Neurotoxicity
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comparison with the Stx2, LPS or vehicle treatments (Figure
7H), while minimum expression of GFAP was observed after
20 days for all treatments (Figure 7N–P).
Dexamethasone reduces the number of reactive
astrocytes
The Dexamethasone treatment significantly reduced the
expression levels of GFAP in all treated groups, except in the
vehicle one (Figure 8J), and it concomitantly also reduced the
number of reactive astrocytes.
Discussion
Various authors have reported that systemic infection with
Stx2 or STEC causes brain damage in different animal models
[39–41]. However, the contribution of LPS secreted by EHEC
to brain damage by Stx2 has not been considered. The present
study has shown strong evidence that LPS enhances the
cytotoxic action of Stx2 in microvasculature, astrocytes and
neurons of mice motor cortex. This is consistent with previous
findings by other authors showing that in vitro administration of
Stx2 together with LPS results in an enhanced synergistic
cytotoxic effect compared with Stx2 alone on human umbilical
vein endothelial cells [42], and also that anti-LPS antibodies
belonging to the O157:H7 serotype have been found in the
serum of HUS patients along with clinical evidence of
endotoxemia [43,44]. Stx2 alone is not enough to obtain a
complete murine model of HUS infection but such model
should also include LPS [45]. Therefore, the present study
aimed to determine for the first time the contribution of secreted
LPS to the encephalopathy caused by the systemic
administration of a sub-lethal dose of Stx2 in a murine model
that emulates a pathological condition observed in patients
infected with Stx2 who suffer from acute encephalopathy.
The alterations observed in the microvasculature support the
fact that Stx2 crosses the blood–brain barrier [34,35]. In line
with this observation, in the present study it was observed that
co-treatment with Stx2 and LPS led to significant alteration of
the endothelium involving discontinuity of the endothelial
glycocalyx and compromising the integrity of the blood–brain
Figure 4.  Dexamethasone restores the expression of VEGF.  Micrographs show the expression of VEGF by
immunofluorescence in mice motor cortex after four days of treatment with saline (A and E), LPS (B and F), Stx2 (C and G) and
Stx2+LPS (D and H) followed by i.p. injection of saline (without Dexamethasone, A through D) or Dexamethasone (E through H).
VEGF expression is quantified under different treatments (I). J: negative control by not adding the primary antibody. *: significant
differences between mice treated with Dexamethasone and those treated with saline (p <0.001).
doi: 10.1371/journal.pone.0070020.g004
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barrier. It is known that the glycocalyx contributes to vascular
protection in vessel walls [46] and to maintenance of vascular
permeability [47,48]. Therefore, the intact glycocalyx is
necessary for the maintenance of normal vascular function and
its discontinuity compromises integrity of the blood–brain
barrier [49]. Damage to the endothelium was progressive and it
Figure 5.  Changes in the expression of NeuN.  Micrographs show immunofluorescence staining for NeuN in the nucleus of
neurons in the motor cortex labeled with anti-NeuN. A, E, I and M: vehicle; B, F, J and N: LPS; C, G, K and O: Stx2; D, H, L and P:
Stx2+LPS; at two, four, seven and twenty days after the respective treatment. Arrows show nuclei of degenerating neurons (H);
asterisk shows normal nuclei of neurons (A). Quantification of phenotypic nuclear abnormalities in neurons at different days and for
different treatments (Q). *: significant differences among all treated and control groups, ** significant differences between Stx2 and
Stx2+LPS treatments (p <0.001).
doi: 10.1371/journal.pone.0070020.g005
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coincided with maximum damage of neurons and astrocytes
after the fourth day of treatment.
Endothelial cell damage was accompanied by a decrease in
the expression of VEGF. This event was previously observed in
primary culture of human podocytes treated with Stx [50] and it
supports our findings. Recent reports indicate that alteration or
loss of VEGF contributes to degeneration of neurons [51] and
this may have occurred in our animal model. Conversely,
VEGF treatment enhances neuronal survival and neurite
outgrowth in explanted brain cortex or substantia nigra [51,52],
as well as maturation in primary cortical neurons [53] in
response to different stress situations [51,53]. However,
whether the neurotrophic effects of VEGF protect neurons or
are mediated indirectly by glial cells still remains to be
elucidated. Therefore, co-treatment of Stx2 and LPS may
reduce VEGF expression that could contribute to neuronal
degeneration.
In the present model of Stx2+LPS injury, the BBB became
more permeable and therefore the toxin reached the brain
parenchyma. This is consistent with previous studies showing
that co-administration of Stx and LPS results in more severe
hemorrhage compared with Stx2 alone [54]. Accordingly,
astrocytes, which also constitute the neurovascular unit,
become injured [35,55]. They are the largest number of cells in
the CNS and react in response to all types of insults [32] such
as trauma, ischemia, neurodegenerative [56] or infective
diseases [57] through a phenomenon known as astrogliosis. At
this stage GFAP is dramatically deregulated [32] and LPS may
produce and/or regulate specific aspects of reactive astrocytes
during inflammatory processes [58].
Direct damage to neurons by Stx2 has been previously
demonstrated [35]. Systemic administration of the toxin in this
study also caused neuronal damage. Co-administration of both
toxins increased the number of damaged neurons. Possible
deleterious actions of pro-inflammatory and/or other elements
raised by Stx2 and LPS on neuronal damage should also be
taken into account and are currently under consideration for
future research. It is known that LPS produces an immune
response that causes increased production of TNFα and IL-1β
in microglia through the p38α mitogen-activated protein kinase,
leading to neurotoxicity [59,60]. In addition, it has been
observed that co-cultures of microglia and neurons treated with
Figure 6.  Dexamethasone decreases the percentage of degenerative neurons.  Micrographs show the expression of NeuN by
immunofluorescence in mice motor cortex immunolabeled with anti-NeuN antibody after four days of treatment with saline (A and
E), LPS (B and F), Stx2 (C and G), Stx2+LPS (D and H) followed by i.p. injection of saline (A through D) or Dexamethasone (E
through H). Dexamethasone protected neurons from the cytotoxic action of LPS, Stx2 and Stx2+LPS (I). J: negative control by not
adding the primary antibody. *: significant differences between mice treated with Dexamethasone and those treated with saline (p
<0.001).
doi: 10.1371/journal.pone.0070020.g006
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LPS release TNFα, causing loss of synaptic proteins and
eventually neuronal death [60].
In our model mechanisms involving inflammatory responses
could indicate the microglia as a central target for the effects of
both toxins, as it belongs to the monocyte-macrophage lineage
Figure 7.  A sub-lethal dose of the toxins causes reactive astrocytes.  Immunofluorescence using an anti-GFAP antibody was
employed to show reactive astrocytes in mice motor cortex. A, E, I and M: saline-treated astrocytes; B, F, J and N: LPS-treated
astrocytes; C, G, K and O: Stx2-treated astrocytes; D, H, L and P: Stx2+LPS-treated astrocytes; at two, four, seven and twenty days
after the respective treatment. Some reactive astrocytes contact microvessels that express VEGF (Q). Quantification of reactive
astrocytes (R). Stx2+LPS treatment caused maximum astrocyte reaction (H). *: significant differences between toxin-treated and
control groups, **: significant differences between Stx2 and Stx2+LPS treatments (p <0.001).
doi: 10.1371/journal.pone.0070020.g007
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[61]. It has been reported that peripheral blood monocytes,
granulocytes and alveolar macrophages are targets of Stx2
binding and toxicity through the Gb3 receptor [62]. In addition,
it has been demonstrated that Ricin, a toxin with RNA N-
glycosidases of 28S RNA action that presents the same
ribotoxicity as Stx2 [63], is responsible for initiating upstream
events that lead to inflammatory responses [64] by activation of
stress-activated protein kinases (SAPKs) [65]. Therefore it is
posited that the microglia may mediate the observed
neurotoxicity through the SAPKs pathway, in a way similar to
macrophage response to Stx2 or Ricin.
As reported by some authors, the use of antibiotics is not
recommended in STEC infections as this may release more
Stx2 into the digestive tract [66]. Accordingly, administration of
the antibiotic ciprofloxacin to mice infected with E. coli O157:H7
resulted in the production of elevated levels of Stx2 [67], which
would increase the chances of the condition being aggravated
by HUS in children and adults [68–70]. Consequently, it is
important to develop a treatment with neuroprotective agents.
Dexamethasone has proved to be a good neuroprotective
candidate as in previous experiments we found that it
increases survival of mice challenged with two lethal doses of
Stx2 by 50% (unpublished data). Dexamethasone is a
glucocorticoid and one of the most common corticosteroids
used in medicine. Its biological response is thirty times more
potent than endogenous cortisol [71], it succeeds in reducing
plasma IL-1β and it may provide neuroprotective effects [72].
Dexamethasone also increases the expression of occludin, a
protein present in tight junctions localized between BBB
endothelial cells [71], making the BBB less permeable. In the
present study it was observed that Dexamethasone rescued
the integrity of the neurovascular unit function following the
detrimental action of both toxins by restoring the normal
distribution of the endothelial glycocalyx and the basal
expression of VEGF. Moreover, it significantly decreased the
astrocyte reaction in all treatments and rescued about 60% of
neurons from a degenerative phenotype. This drug therefore
appears to reduce inflammation and BBB permeability in the
CNS.
The differences observed in cell damage in the brain cortex
between the treatments employing Stx2 free of LPS and Stx2
with LPS were conclusive. In the encephalopathy mediated by
Figure 8.  Dexamethasone reduces reactive astrocytes.  Micrographs show the expression of GFAP by immunofluorescence
with anti-GFAP antibody in astrocytes after four days of treatment with saline (A and E), LPS (B and F), Stx2 (C and G) and
Stx2+LPS (D and H) followed by i.p. injection of saline (A through D) or Dexamethasone (E through H). Quantification of reactive
astrocytes (I) under all treatments. J: negative control by not adding the primary antibody. *: significant differences between mice
treated with Dexamethasone and those treated with saline (p <0.001).
doi: 10.1371/journal.pone.0070020.g008
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Stx2, the contribution of LPS and the inflammatory agents
produced are significantly relevant and so cannot be ignored
[43,44,73].
In conclusion, co-treatment with Stx2 and LPS increased the
cytotoxic effects of Stx2 but Dexamethasone, a potent anti-
inflammatory, protected neuronal integrity and decreased
cerebral damage. Conversely, Dexamethasone treatment
suggests that cytokines such as TNF-α and/or IL-1β may be
involved in the encephalopathy.
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